KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EBT (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EBT for 17 consecutive years, with $929.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 202.23% to $929.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $995.5 million through Dec 2025, up 142.5% year-over-year, with the annual reading at $995.5 million for FY2025, 142.5% up from the prior year.
  • EBT for Q4 2025 was $929.2 million at Bio-Rad Laboratories, up from -$431.1 million in the prior quarter.
  • The five-year high for EBT was $5.0 billion in Q3 2021, with the low at -$4.4 billion in Q1 2022.
  • Average EBT over 5 years is -$72.6 million, with a median of $111.0 million recorded in 2023.
  • The sharpest move saw EBT crashed 436.73% in 2022, then soared 528.45% in 2024.
  • Over 5 years, EBT stood at -$2.0 billion in 2021, then soared by 153.84% to $1.1 billion in 2022, then plummeted by 60.75% to $428.4 million in 2023, then crashed by 312.16% to -$908.9 million in 2024, then skyrocketed by 202.23% to $929.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $929.2 million, -$431.1 million, and $414.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.